Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Soil | 12 | 2026 | 76 | 5.310 |
Why?
|
| Helminths | 13 | 2026 | 51 | 4.860 |
Why?
|
| Intestinal Diseases, Parasitic | 12 | 2025 | 41 | 4.510 |
Why?
|
| Helminthiasis | 13 | 2026 | 83 | 4.390 |
Why?
|
| Parasites | 9 | 2025 | 35 | 4.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 15 | 2025 | 530 | 3.340 |
Why?
|
| Feces | 24 | 2025 | 724 | 2.560 |
Why?
|
| DNA, Helminth | 5 | 2024 | 23 | 2.360 |
Why?
|
| Strongyloidiasis | 8 | 2025 | 50 | 1.870 |
Why?
|
| Strongyloides stercoralis | 11 | 2025 | 24 | 1.850 |
Why?
|
| Chagas Disease | 4 | 2025 | 314 | 1.720 |
Why?
|
| Anthelmintics | 4 | 2025 | 55 | 1.720 |
Why?
|
| DNA, Protozoan | 6 | 2025 | 34 | 1.650 |
Why?
|
| Coinfection | 7 | 2026 | 190 | 1.570 |
Why?
|
| Rural Population | 8 | 2024 | 256 | 1.290 |
Why?
|
| Trypanosoma cruzi | 4 | 2025 | 256 | 1.270 |
Why?
|
| Trichuris | 4 | 2025 | 26 | 1.260 |
Why?
|
| Hookworm Infections | 4 | 2024 | 125 | 1.220 |
Why?
|
| Antigens, Protozoan | 2 | 2025 | 80 | 1.130 |
Why?
|
| Toxocara | 2 | 2026 | 15 | 1.120 |
Why?
|
| Animals | 46 | 2026 | 34278 | 1.120 |
Why?
|
| Albendazole | 2 | 2025 | 27 | 1.120 |
Why?
|
| Trichuriasis | 2 | 2025 | 31 | 1.090 |
Why?
|
| Taenia solium | 3 | 2015 | 11 | 1.030 |
Why?
|
| Soil Microbiology | 2 | 2026 | 19 | 1.030 |
Why?
|
| Dengue | 2 | 2025 | 123 | 1.020 |
Why?
|
| Sensitivity and Specificity | 14 | 2025 | 2122 | 1.020 |
Why?
|
| Ascomycota | 1 | 2026 | 27 | 0.960 |
Why?
|
| Neurocysticercosis | 2 | 2015 | 25 | 0.910 |
Why?
|
| Leishmaniasis | 1 | 2025 | 40 | 0.900 |
Why?
|
| Dog Diseases | 1 | 2025 | 58 | 0.900 |
Why?
|
| Ivermectin | 1 | 2024 | 8 | 0.890 |
Why?
|
| Hemoglobins | 1 | 2025 | 318 | 0.830 |
Why?
|
| HIV Infections | 5 | 2025 | 2031 | 0.810 |
Why?
|
| Sanitation | 2 | 2025 | 16 | 0.780 |
Why?
|
| Prevalence | 11 | 2025 | 2681 | 0.760 |
Why?
|
| Brugia malayi | 1 | 2022 | 39 | 0.730 |
Why?
|
| Isosporiasis | 1 | 2021 | 3 | 0.730 |
Why?
|
| Giardia lamblia | 5 | 2023 | 10 | 0.730 |
Why?
|
| Ecuador | 6 | 2025 | 14 | 0.710 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 321 | 0.700 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 313 | 0.690 |
Why?
|
| Mycobacterium tuberculosis | 5 | 2024 | 422 | 0.690 |
Why?
|
| Eosinophilia | 2 | 2021 | 105 | 0.680 |
Why?
|
| Vaccines | 1 | 2026 | 385 | 0.670 |
Why?
|
| Intestines | 3 | 2020 | 585 | 0.670 |
Why?
|
| Poverty | 2 | 2024 | 451 | 0.670 |
Why?
|
| Diarrhea | 2 | 2023 | 311 | 0.660 |
Why?
|
| Beds | 1 | 2020 | 9 | 0.650 |
Why?
|
| Parasite Egg Count | 5 | 2024 | 28 | 0.650 |
Why?
|
| Vaccination | 1 | 2026 | 1036 | 0.650 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 130 | 0.640 |
Why?
|
| Dust | 1 | 2020 | 31 | 0.640 |
Why?
|
| Humans | 59 | 2026 | 130931 | 0.630 |
Why?
|
| Vitamin B 12 | 1 | 2020 | 59 | 0.630 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 225 | 0.620 |
Why?
|
| Family Characteristics | 1 | 2020 | 98 | 0.610 |
Why?
|
| Malaria, Falciparum | 2 | 2026 | 70 | 0.590 |
Why?
|
| Organ Transplantation | 1 | 2020 | 174 | 0.560 |
Why?
|
| Parasite Load | 1 | 2017 | 31 | 0.540 |
Why?
|
| Tuberculosis | 5 | 2024 | 552 | 0.540 |
Why?
|
| Ancylostomatoidea | 2 | 2024 | 62 | 0.500 |
Why?
|
| Inflammation | 5 | 2025 | 1480 | 0.490 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2024 | 73 | 0.480 |
Why?
|
| Pilot Projects | 5 | 2025 | 1441 | 0.480 |
Why?
|
| Child | 19 | 2026 | 26098 | 0.470 |
Why?
|
| Hypereosinophilic Syndrome | 2 | 2013 | 9 | 0.470 |
Why?
|
| DNA | 2 | 2022 | 1444 | 0.460 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2024 | 236 | 0.450 |
Why?
|
| Antibodies, Protozoan | 2 | 2025 | 99 | 0.450 |
Why?
|
| Developed Countries | 1 | 2014 | 44 | 0.440 |
Why?
|
| Female | 28 | 2026 | 70755 | 0.430 |
Why?
|
| Emigration and Immigration | 1 | 2014 | 81 | 0.430 |
Why?
|
| Alabama | 3 | 2025 | 44 | 0.410 |
Why?
|
| Parasitic Diseases | 1 | 2014 | 59 | 0.410 |
Why?
|
| Plasmodium falciparum | 2 | 2026 | 96 | 0.410 |
Why?
|
| Cysticercosis | 1 | 2013 | 22 | 0.400 |
Why?
|
| Global Health | 2 | 2017 | 631 | 0.400 |
Why?
|
| Brain Edema | 1 | 2013 | 65 | 0.400 |
Why?
|
| Child, Preschool | 12 | 2026 | 14945 | 0.400 |
Why?
|
| Granuloma | 1 | 2013 | 63 | 0.390 |
Why?
|
| Adult | 19 | 2025 | 31541 | 0.380 |
Why?
|
| Ascaris lumbricoides | 3 | 2018 | 19 | 0.370 |
Why?
|
| Developing Countries | 1 | 2014 | 303 | 0.370 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2013 | 331 | 0.370 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 830 | 0.370 |
Why?
|
| Calcinosis | 1 | 2013 | 185 | 0.360 |
Why?
|
| Serologic Tests | 3 | 2025 | 125 | 0.360 |
Why?
|
| Antibodies, Helminth | 4 | 2025 | 131 | 0.360 |
Why?
|
| Neglected Diseases | 1 | 2014 | 152 | 0.350 |
Why?
|
| Cryptosporidium | 3 | 2017 | 27 | 0.350 |
Why?
|
| Male | 24 | 2026 | 64823 | 0.350 |
Why?
|
| Schistosomiasis | 2 | 2024 | 52 | 0.350 |
Why?
|
| Environment | 2 | 2024 | 149 | 0.350 |
Why?
|
| Latin America | 2 | 2026 | 101 | 0.340 |
Why?
|
| Giardiasis | 2 | 2023 | 10 | 0.340 |
Why?
|
| Ancylostomiasis | 2 | 2024 | 62 | 0.340 |
Why?
|
| Young Adult | 8 | 2025 | 10040 | 0.330 |
Why?
|
| Adolescent | 11 | 2025 | 20814 | 0.330 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2024 | 172 | 0.320 |
Why?
|
| Middle Aged | 15 | 2025 | 28735 | 0.310 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 265 | 0.310 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2025 | 790 | 0.300 |
Why?
|
| Bacterial Translocation | 2 | 2025 | 24 | 0.300 |
Why?
|
| Antigens, Helminth | 2 | 2025 | 187 | 0.290 |
Why?
|
| Necator americanus | 3 | 2025 | 91 | 0.280 |
Why?
|
| Seizures | 1 | 2013 | 875 | 0.280 |
Why?
|
| Immunoglobulin G | 3 | 2026 | 810 | 0.280 |
Why?
|
| Anemia, Sickle Cell | 1 | 2012 | 328 | 0.280 |
Why?
|
| Blastocystis | 3 | 2025 | 6 | 0.280 |
Why?
|
| Ancylostoma | 3 | 2024 | 98 | 0.270 |
Why?
|
| Urban Population | 3 | 2020 | 281 | 0.270 |
Why?
|
| Emigrants and Immigrants | 3 | 2025 | 169 | 0.260 |
Why?
|
| Ascariasis | 2 | 2018 | 73 | 0.260 |
Why?
|
| Infant | 5 | 2025 | 13210 | 0.250 |
Why?
|
| Seroepidemiologic Studies | 2 | 2025 | 167 | 0.250 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3799 | 0.240 |
Why?
|
| Waste Disposal, Fluid | 1 | 2025 | 7 | 0.240 |
Why?
|
| Uganda | 3 | 2025 | 94 | 0.240 |
Why?
|
| Recombinant Proteins | 3 | 2025 | 1311 | 0.240 |
Why?
|
| DNA, Fungal | 1 | 2026 | 76 | 0.240 |
Why?
|
| Texas | 3 | 2025 | 3604 | 0.240 |
Why?
|
| Entamoeba histolytica | 2 | 2017 | 17 | 0.240 |
Why?
|
| Necatoriasis | 1 | 2025 | 37 | 0.240 |
Why?
|
| Sputum | 2 | 2024 | 118 | 0.230 |
Why?
|
| Sewage | 1 | 2025 | 11 | 0.230 |
Why?
|
| Species Specificity | 3 | 2017 | 519 | 0.230 |
Why?
|
| Peru | 1 | 2025 | 56 | 0.230 |
Why?
|
| Leishmania | 1 | 2025 | 33 | 0.230 |
Why?
|
| Public Opinion | 1 | 2026 | 63 | 0.230 |
Why?
|
| Protozoan Infections | 1 | 2025 | 15 | 0.220 |
Why?
|
| South Carolina | 1 | 2024 | 10 | 0.220 |
Why?
|
| Schistosoma | 1 | 2024 | 13 | 0.220 |
Why?
|
| Mississippi | 1 | 2024 | 35 | 0.220 |
Why?
|
| Dogs | 1 | 2025 | 623 | 0.220 |
Why?
|
| Louisiana | 1 | 2024 | 135 | 0.210 |
Why?
|
| Mexico | 1 | 2024 | 197 | 0.210 |
Why?
|
| Dengue Virus | 1 | 2025 | 134 | 0.210 |
Why?
|
| Social Media | 1 | 2026 | 118 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 1256 | 0.200 |
Why?
|
| Water | 1 | 2024 | 188 | 0.200 |
Why?
|
| Pyrethrins | 1 | 2022 | 9 | 0.190 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 32 | 0.190 |
Why?
|
| Arboviruses | 1 | 2022 | 25 | 0.190 |
Why?
|
| Receptors, Interleukin-5 | 1 | 2022 | 5 | 0.190 |
Why?
|
| Insecticides | 1 | 2022 | 47 | 0.190 |
Why?
|
| Interleukin-5 | 1 | 2022 | 49 | 0.180 |
Why?
|
| Isospora | 1 | 2021 | 3 | 0.180 |
Why?
|
| BCG Vaccine | 2 | 2022 | 109 | 0.180 |
Why?
|
| Aedes | 1 | 2022 | 101 | 0.180 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 44 | 0.180 |
Why?
|
| Rabbits | 1 | 2022 | 632 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1511 | 0.170 |
Why?
|
| Mozambique | 3 | 2026 | 23 | 0.170 |
Why?
|
| Zika Virus | 1 | 2022 | 156 | 0.170 |
Why?
|
| Intestinal Mucosa | 1 | 2025 | 762 | 0.170 |
Why?
|
| Blastocystis Infections | 1 | 2020 | 5 | 0.160 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2020 | 10 | 0.160 |
Why?
|
| Zika Virus Infection | 1 | 2022 | 179 | 0.160 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2020 | 13 | 0.160 |
Why?
|
| RNA Interference | 1 | 2022 | 497 | 0.160 |
Why?
|
| Environmental Microbiology | 1 | 2020 | 15 | 0.160 |
Why?
|
| Eosinophils | 1 | 2020 | 125 | 0.160 |
Why?
|
| Genes, Bacterial | 1 | 2020 | 216 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2026 | 896 | 0.150 |
Why?
|
| Argentina | 2 | 2017 | 54 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2017 | 228 | 0.150 |
Why?
|
| Metagenomics | 1 | 2020 | 114 | 0.150 |
Why?
|
| Colombia | 3 | 2024 | 50 | 0.140 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 17 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1559 | 0.140 |
Why?
|
| Mass Drug Administration | 1 | 2018 | 12 | 0.140 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 355 | 0.140 |
Why?
|
| Microbiota | 1 | 2023 | 438 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2024 | 12858 | 0.130 |
Why?
|
| Th1 Cells | 1 | 2018 | 155 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2950 | 0.130 |
Why?
|
| Risk Factors | 3 | 2025 | 10901 | 0.130 |
Why?
|
| Microscopy | 2 | 2020 | 123 | 0.130 |
Why?
|
| Entamoeba | 1 | 2016 | 3 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2575 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 261 | 0.120 |
Why?
|
| Aged | 4 | 2025 | 21134 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 694 | 0.110 |
Why?
|
| Head Movements | 1 | 2015 | 18 | 0.110 |
Why?
|
| United States | 4 | 2015 | 11718 | 0.110 |
Why?
|
| Vertigo | 1 | 2015 | 35 | 0.110 |
Why?
|
| Cerebral Ventricles | 1 | 2015 | 81 | 0.110 |
Why?
|
| Asia | 1 | 2014 | 125 | 0.110 |
Why?
|
| Vomiting | 1 | 2015 | 104 | 0.110 |
Why?
|
| Africa | 1 | 2014 | 141 | 0.110 |
Why?
|
| Headache | 1 | 2015 | 110 | 0.110 |
Why?
|
| Parasitology | 1 | 2014 | 7 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 496 | 0.110 |
Why?
|
| DNA Primers | 2 | 2013 | 609 | 0.100 |
Why?
|
| Cysticercus | 1 | 2013 | 2 | 0.100 |
Why?
|
| Europe | 1 | 2014 | 371 | 0.100 |
Why?
|
| Mali | 1 | 2013 | 12 | 0.100 |
Why?
|
| Empirical Research | 1 | 2013 | 10 | 0.100 |
Why?
|
| Poverty Areas | 2 | 2025 | 36 | 0.100 |
Why?
|
| Honduras | 2 | 2025 | 25 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2025 | 6443 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2018 | 5096 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 133 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 372 | 0.100 |
Why?
|
| Antinematodal Agents | 1 | 2012 | 11 | 0.100 |
Why?
|
| Sierra Leone | 1 | 2012 | 19 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 387 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2025 | 17485 | 0.090 |
Why?
|
| India | 1 | 2013 | 245 | 0.090 |
Why?
|
| North America | 1 | 2013 | 256 | 0.090 |
Why?
|
| Syndrome | 1 | 2015 | 1154 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 117 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 741 | 0.090 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 492 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2012 | 191 | 0.090 |
Why?
|
| Neuroimaging | 1 | 2015 | 388 | 0.090 |
Why?
|
| Biomarkers | 3 | 2025 | 3365 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2018 | 1082 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2013 | 1225 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 4008 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 222 | 0.080 |
Why?
|
| Zoonoses | 2 | 2024 | 52 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 294 | 0.080 |
Why?
|
| Cytokines | 2 | 2026 | 1340 | 0.080 |
Why?
|
| Recurrence | 1 | 2013 | 1473 | 0.080 |
Why?
|
| Hypersensitivity | 1 | 2012 | 230 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2025 | 448 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 1153 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6862 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 671 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1904 | 0.060 |
Why?
|
| Genotype | 1 | 2012 | 2651 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 35 | 0.060 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2025 | 53 | 0.060 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2025 | 36 | 0.060 |
Why?
|
| Water Purification | 1 | 2025 | 19 | 0.060 |
Why?
|
| Drinking Water | 1 | 2025 | 16 | 0.060 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2025 | 36 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2018 | 542 | 0.060 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2004 | 1 | 0.060 |
Why?
|
| Schistosoma mansoni | 1 | 2004 | 24 | 0.060 |
Why?
|
| Immunoassay | 1 | 2025 | 133 | 0.060 |
Why?
|
| Schistosomiasis mansoni | 1 | 2004 | 24 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 1490 | 0.050 |
Why?
|
| Pets | 1 | 2024 | 19 | 0.050 |
Why?
|
| Giardia | 1 | 2023 | 1 | 0.050 |
Why?
|
| Tanzania | 1 | 2024 | 70 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2025 | 418 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2025 | 428 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3833 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 298 | 0.050 |
Why?
|
| Phenazines | 1 | 2022 | 9 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 3161 | 0.050 |
Why?
|
| Alginates | 1 | 2022 | 23 | 0.050 |
Why?
|
| Insecticide Resistance | 1 | 2022 | 30 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 67 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 94 | 0.050 |
Why?
|
| Mosquito Vectors | 1 | 2022 | 36 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 63 | 0.050 |
Why?
|
| Nitriles | 1 | 2022 | 164 | 0.050 |
Why?
|
| Swine | 1 | 2025 | 1188 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 193 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2022 | 191 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 34 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 64 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1500 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2020 | 28 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 21 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2022 | 264 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2025 | 981 | 0.040 |
Why?
|
| Bacteria | 1 | 2022 | 530 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 64 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 87 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2018 | 74 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2018 | 144 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 38 | 0.030 |
Why?
|
| Timor-Leste | 1 | 2017 | 1 | 0.030 |
Why?
|
| World Health Organization | 1 | 2018 | 115 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2017 | 138 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 931 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 184 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2017 | 124 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 238 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2017 | 185 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 155 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 391 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1157 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 706 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 646 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 18410 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 4738 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2965 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 4681 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1248 | 0.020 |
Why?
|
| Animal Structures | 1 | 2011 | 9 | 0.020 |
Why?
|
| Alum Compounds | 1 | 2011 | 42 | 0.020 |
Why?
|
| HIV | 1 | 2012 | 178 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1302 | 0.020 |
Why?
|
| Larva | 1 | 2011 | 252 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 153 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2459 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8542 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 405 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2012 | 513 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 302 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 549 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 392 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 1018 | 0.020 |
Why?
|
| HIV-1 | 1 | 2012 | 477 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2018 | 2430 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1523 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5257 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 236 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 291 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1768 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2004 | 156 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 256 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 593 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2004 | 656 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2560 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 2781 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3610 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 1741 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1790 | 0.010 |
Why?
|